Friday 6 November 2026 Export TVTX’s income statement to Excel — free account

Travere Therapeutics, Inc.

Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.

Revenue: +36.2%
EPS: −290.7%
Free cash flow: +6,379.8%
Total debt: +93.8%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

49.45 0.58 +1.19%

Follow TVTX

Alert me

Market cap: $4.7B
P/E: 0.0×
Fwd P/E: −145×
Dividend yield: —
F-score: 6/9
Altman Z: 1.78
Beneish M: −1.74
Dividend safety: n/a

Overview

Travere Therapeutics, Inc. (TVTX) P/B ratio

Alert me on P/B ratio

As of 6 November 2026, Travere Therapeutics, Inc. (TVTX) trades at a P/B ratio of 207×. Over the past ten years it has ranged from 0.0× (December 2024) to 257× (August 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 2.1× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TVTX/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Travere Therapeutics, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TVTX/metrics/pb-ratio">Travere Therapeutics, Inc. (TVTX) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	29.7×	27.62%
FY2024	23.3×	557.94%
FY2023	3.5×	(88.50%)
FY2022	30.7×	400.07%
FY2021	6.1×	0.19%
FY2020	6.1×	125.73%
FY2019	2.7×	(5.46%)
FY2018	2.9×	(3.26%)
FY2017	3.0×	33.99%
FY2016	2.2×	2.78%

Period	P/B ratio	Change
Sep 2026	247×	13.92%
Jun 2026	217×	683.35%
Mar 2026	27.6×	(6.87%)
Dec 2025	29.7×	2.40%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 257×

Ten-year median 3.5×

Current reading's percentile 97

Company	P/B ratio
CRSP CRISPR Therapeutics AG compare	2.9×
EWTX Edgewise Therapeutics, Inc. compare	3.0×
LEGN Legend Biotech Corporation Sponsored ADR compare	3.6×
DNTH Dianthus Therapeutics, Inc. compare	4.0×
DFTX Definium Therapeutics, Inc. compare	4.0×
MANE Veradermics Incorporated compare	6.9×
COGT Cogent Biosciences, Inc. compare	11.6×
ERAS Erasca, Inc. compare	12.3×
TVTX Travere Therapeutics, Inc.	207×
Biotechnology industry median	2.1×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Travere Therapeutics, Inc. (TVTX) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on TVTX

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on TVTX

Stockrow Weekly